Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Early Data Suggest Novo Nordisk's Degludec Comparable To Sanofi's Lantus

Executive Summary

Novo Nordisk has a good start for its ultra-long acting insulin Degludec, with much-anticipated Phase II data released at the American Diabetes Association annual scientific sessions June 25 showing that Degludec is as good as Sanofi-Aventis's Lantus (insulin glargine). However, to unseat the market leader, the Danish firm will need to show its insulin analog is superior in either maintaining blood glucose control or reducing the incidence of hypoglycemia


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts